Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Vascular Biogen. Ord (VBLT)

Vascular Biogen. Ord (VBLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,417
  • Shares Outstanding, K 69,327
  • Annual Sales, $ 770 K
  • Annual Income, $ -29,920 K
  • 60-Month Beta 0.57
  • Price/Sales 21.21
  • Price/Cash Flow N/A
  • Price/Book 0.47
Trade VBLT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.46
  • Most Recent Earnings -0.12 on 08/15/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 593.56% ( +4.22%)
  • Historical Volatility 456.04%
  • IV Percentile 98%
  • IV Rank 70.34%
  • IV High 812.08% on 08/04/22
  • IV Low 75.40% on 01/26/22
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 140
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 36,294
  • Open Int (30-Day) 36,135

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2101 +8.71%
on 08/01/22
0.4777 -52.19%
on 07/20/22
-1.8216 (-88.86%)
since 07/19/22
3-Month
0.2101 +8.71%
on 08/01/22
2.2000 -89.62%
on 07/11/22
-1.3216 (-85.26%)
since 05/19/22
52-Week
0.2101 +8.71%
on 08/01/22
2.5400 -91.01%
on 11/11/21
-1.7216 (-88.29%)
since 08/19/21

Most Recent Stories

More News
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VBLT : 0.2284 (-3.55%)
XRAY : 35.78 (-1.60%)
Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 17.33% and 121.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RAPT : 26.69 (-3.61%)
VBLT : 0.2284 (-3.55%)
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

VIR : 24.65 (-0.92%)
VBLT : 0.2284 (-3.55%)
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

APLS : 64.92 (-0.89%)
VBLT : 0.2284 (-3.55%)
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBLT : 0.2284 (-3.55%)
ADMA : 2.55 (+1.59%)
Repligen (RGEN) Tops Q2 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 26.39% and 9.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RGEN : 237.75 (-1.43%)
VBLT : 0.2284 (-3.55%)
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails

Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.

ALKS : 25.26 (+0.08%)
SGEN : 171.67 (+1.53%)
VBLT : 0.2284 (-3.55%)
BNTX : 147.92 (+0.21%)
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) -...

VBLT : 0.2284 (-3.55%)
VBL Therapeutics to Participate in the Jefferies Healthcare Conference

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company...

VBLT : 0.2284 (-3.55%)
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VBLT : 0.2284 (-3.55%)
EVGN : 1.2000 (-3.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment...

See More

Key Turning Points

3rd Resistance Point 0.2498
2nd Resistance Point 0.2429
1st Resistance Point 0.2357
Last Price 0.2284
1st Support Level 0.2216
2nd Support Level 0.2147
3rd Support Level 0.2075

See More

52-Week High 2.5400
Fibonacci 61.8% 1.6500
Fibonacci 50% 1.3750
Fibonacci 38.2% 1.1001
Last Price 0.2284
52-Week Low 0.2101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar